POWER
Regimen
- Experimental
- cisplatin/5-FU + panitumumab (CFP)
- Control
- cisplatin/5-FU (CF)
Population
Non-resectable advanced or metastatic ESCC, first-line
Key finding
mOS 10.2 vs 9.4 mo (CF vs CFP; HR 1.17, p=0.43); trial stopped early for FUTILITY + safety; grade 5 events 4.3% vs 23.6%
Source: PMID 31959339
Timeline
Guideline citations
- NCCN ESOPHAGEAL (p.145)